NNMTi

Description

NNMTi (CAS 42464-96-0) is a nicotinamide N-methyltransferase (NNMT) inhibitor that promotes myoblast differentiation. NNMT is a fundamental cytosolic biotransforming enzyme that catalyzes the N-methylation of endogenous and exogenous xenobiotics. NNMTi treatment combined with lean diet substitution accelerated improved body weight fat loss, increased whole-body lean mass to body weight ratio, reduced liver epididymal white adipose tissue weights, decreased liver adiposity, improved hepatic steatosis, relative to a lean diet substitution alone.

Chemical Properties

Brown solid.

Uses

NNMTi is an enzyme overexpressed during skeletal muscle aging and is associated with the repair of damage to the NAD+ pathway, dysregulation of sirtuin1 activity, and increased senescence of muscle stem cells.

Preparation

Synthesis of 5-Amino-1-methyl-1-quinolinium Iodide(NNMTi): Iodomethane (0.160 ml, 0.365 g, 2.6 mmol) was added to a solution of 5-aminoquinoline (0.277 g, 1.9 mmol) in tetrahydrofuran (7 ml), and stirred at room temperature for 1 day until a red solid precipitated. After filtration, the filter cake was washed with tetrahydrofuran (2 x 5 ml) and dried under vacuum to give 0.240 g of compound 5-Amino-1-methyl-1-quinolinium Iodide.

Biological Activity

NNMTi is a potent nicotinamide N-methyltransferase (NNMT) inhibitor (IC50=1.2 μM), selectively binding to NNMT substrate binding site residues. NNMTi can promote myoblast differentiation in vitro and enhance the fusion and regeneration of muscle stem cells in aged mice.

in vitro

NNMTi (10-30 μM; 96 hours) produces a concentration-related increase in myoblast differentiation on C2C12 myoblast differentiation. 30 μM NNMTi results in 18% MHC-positive myotube nuclei, representing a 45% increase in the extent of myoblast differentiation compared to untreated differentiating myoblasts (12% MHC-positive myotube nuclei).

in vivo

NNMTi (subcutaneous (SC) injection; 5 mg/kg and 10 mg/kg; 2 weeks (1 week pre-injury and 1 week post-injury)) has an effect on muscle regeneration after injury, it results in 60% and 75% higher incidence of proliferating/active muSCs at 5 mg/kg and 10 mg/kg, respectively. The relative numbers of fibers with an EdU + myonucleus increased 40% and 48% with NNMTi treatment at 5 mg/kg and 10 mg/kg, respectively. The odds ratio of fused myonuclei for control are 0.58 and 0.53 times the odds at the low and high NNMTi dose, respectively.NNMTi (subcutaneous injection; 10 mg/kg; 1 week) produces no systemic toxicity in mice, the levels of the glucose, cholesterol, plasma proteins, and electrolytes between control and NNMTi-treated samples show no difference in mice. 1-week post-injury daily repeat-dosing of NNMTi is well tolerated with no untoward systemic toxicity or behavioral implications in aged mice.

storage

Store at -20°C

References

[1]. Harshini Neelakantan, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Pharmacol. 2019 May;163:481-492. DOI:10.1016/j.bcp.2019.02.008
[2]. Harshini Neelakantan, et al. Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase. J Med Chem DOI:10.1021/acs.jmedchem.7b00389
[3]. Mark A Eckert et al. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature, 569(7758), 723-728 (2019-05-03) DOI:10.1038/s41586-019-1173-8
[4]. SAMPSONCATHERINE M. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice.[J]. Scientific Reports, 2021: 5637. DOI:10.1038/s41598-021-85051-6.

Raw materials

Preparation Products